1-855-378-42281-855-378-4228
One of the outpatient rehabilitation options for clients in Pierceton struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed facilities and doctors are authorized to administer specific meds to opioid addicted clients, many that are opioids themselves and are addictive. In low amounts however, the client does not experience being high but also does not experience acute cravings and isn't experiencing opioid withdrawal. Methadone is the first drug administered for this reason, but there are other options to pick from.
Methadone is an opiate and is meant to be taken at an out-patient medical center certified to administer the drug, which is taken daily in liquid or pill form. The cost of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid based drug, and is in pill form often taken every other day. But different from Methadone which can only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is approximately $300.00 monthly for the generic version of the medication. There is also a version of buprenorphine that contains naloxone, that is a drug that reverses the effects of opiates. A person taking this formulation, also known as Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It is also taken every day, and is priced approximately $450 a month. Naltrexone is another medication taken in opioid maintenance therapy, but unlike the other drugs aforementioned it's an opiate blocker and is not an opioid. A person has the choice to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from feeling high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 monthly.
For All Alcohol and Drug Treatment Facilities In Pierceton, Click Here.
